Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of Mavodelpar (REN001) in Primary Mitochondrial Myopathy
NCT05267574Phase 3Terminated
- Sponsor
- Reneo Pharmaceuticals
- Start
- Feb 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 3 trial of mavodelpar in primary mitochondrial myopathy (PMM), sponsored by Reneo Pharmaceuticals. Started Feb 2022; status: terminated.
02
Drugs
mavodelpar
03
Conditions
primary mitochondrial myopathy (PMM)
Beyond the preview
Go deeper on NCT05267574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05267574.